6533b82afe1ef96bd128ba3f
RESEARCH PRODUCT
Effects of desipramine and alprazolam in the forced swim test in rats after long-lasting termination of chronic exposure to picrotoxin and pentylenetetrazol.
M. GaglianoG. CannizzaroM. SabatinoA. FlugyCarla Cannizzarosubject
MalePharmacologyMotor ActivityChlordiazepoxidechemistry.chemical_compoundDesipraminemedicineAnimalsPicrotoxinPharmacology (medical)GABA-A Receptor AntagonistsPentylenetetrazolBiological PsychiatrySwimmingPharmacologyAlprazolamGABAA receptorKindlingbusiness.industryDesipramineChlordiazepoxideRatsSubstance Withdrawal SyndromePsychiatry and Mental healthNeurologyAlprazolamchemistryPentylenetetrazoleNeurology (clinical)businesshuman activitiesPsychomotor Performancemedicine.drugBehavioural despair testPicrotoxindescription
Abstract Rats were treated for 5 weeks with three subconvulsant doses of picrotoxin (PTX) and pentylenetetrazol (PTZ) per week to induce a persistent reduction of the GABA A receptor function which results in chemical kindling. Fifteen days after termination of this treatment schedule, the effect of desipramine (DMI) and alpraxolam (ALP) on immobility time in the forced swim test (FST) was evaluated. Chronic PTX and PTZ did not alter the immobility time. Acute PTX and PTZ reduced the immobility of rats chronically treated with vehicle but not of those exposed chronically to PTX and PTZ. Chronic PTX did not influence the anti-immobility effect of DMI, but blocked that of ALP. Chronic PTZ markedly potentiated the anti-immobility effect of DMI but blocked that of ALP. Concomitant administration of chlordiazepoxide prevented the effects of chronic PTX and PTZ. These findings suggest that a long-lasting reduction in GABA A receptor function, unlike acute reduction, does not play an important role in the mobility of rats in the FST and in the anti-immobility effect of DMI while it blocks that of ALP.
year | journal | country | edition | language |
---|---|---|---|---|
1993-12-01 | European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology |